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Abstract Biphalin is a dimeric opioid peptide that
exhibits afﬁnity for three types of opioid receptors (MOP,
DOP and KOP). Biphalin is undergoing intensive preclin-
ical study. It was recognized that activation of d-opioid
receptor elicits neuroprotection against brain hypoxia and
ischemia. We compare the effect of biphalin and morphine
and the inhibition of opioid receptors by naltrexone on
survival of neurons in rat organotypic hippocampal cul-
tures challenged with NMDA. Findings: (1) 0.025–0.1 lM
biphalin reduces NMDA-induced neuronal damage; (2)
biphalin neuroprotection is abolished by naltrexone; (3)
reduced number of dead cells is shown even if biphalin is
applied with delay after NMDA challenge.
Keywords Neuroprotection  Opioid  Opioid receptor 
Excitotoxicity  Biphalin  Morphine
Introduction
Excitotoxicity is a leading cause of neurodegeneration
observed in progressive and acute brain diseases [1–3].
Despite many years of research on the mechanisms of
neuronal death and search for effective neuroprotectants
there is still no effective therapy [4–6]. Among agents
tested so far, those designed to combine multiple neuro-
protective mechanisms such as the AM-36, seem to have
the greatest neuroprotective effect [7].
Excitotoxicity is associated with pathological changes
(such as excess release of excitatory amino acids, disrup-
tion of ionic homeostasis due to Na
? and Ca
2? inﬂux and
generation of toxic free radicals) as well as with generation
and transmission of pain signal. Pain is a signal of acute
(e.g. wound) or chronic (e.g. inﬂammation) pathological
changes within the body. Therefore, involvement of opi-
oids, which are currently used in severe pain treatments, in
neurodegeneration/neuroprotection mechanisms is impor-
tant ﬁeld of studies [8, 9]. Most of available study indicated
that all opioid receptors are involved in neuroprotection.
Therefore activation of all opioid receptors could result in
more effective neuroprotection than selective ligands
interacting with one type of opioid receptor.
Biphalin (BIPH) is a peptide [10] that hybridizes two
opioid pharmacophores in one. The compound is promot-
ing as a new analgesics following idea that multitarget
receptor ligands could be more effective than speciﬁc to
one type of opioid receptor. Indeed, biphalin exhibits a
high afﬁnity for opioid receptors types MOP and DOP
and lower but signiﬁcant to receptors KOP [11–13].
When administrated directly to central nervous system
(intracerebroventricularly or intrathecally) it has been
shown to be more potent than morphine and ethorphine at
eliciting antinociception [11]. Moreover, BIPH induces less
physical dependence than morphine [14] and express sev-
eral positive additional effects that further rationalize of its
development as a new analgesic [11, 15–17]. Our present
study refers to neuroprotective potential of biphalin and
compares it to the known morphine protection [18, 19]i n
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Materials and Methods
Organotypic Hippocampal Culture
The Local Committee for Ethics in Animal Experiments
approved all the experimental procedures on rat organo-
typic hippocampal culture (OHC). Hippocampal slices
were prepared from 6 to 7 days old Wistar rats according to
the method of Stoppini [20] with slight modiﬁcations [21].
After brief anesthesia with Vetbutal (pentobarbital; Sigma)
ice-cooled pups were plunged into 70% alcohol solution,
decapitated with scissors, and then brains were quickly
removed to ice-cold HBSS (Gibco). Hippopcampi were
separated and cut into 400 lm slices using McIlwain tissue
chopper. Slices were transposed to Millicell-CM (Milli-
pore) membranes for further growth. Millicell-CM mem-
branes in 6-well plates were pre-equilibrated with 1 ml of
culture medium (HEPES pH 7.2, DMEM 50%, HBSS 25%,
Horse Serum 25% (Gibco), 2 mmol/l L-glutamine, 5 mg/ml
glucose, 1% amphotericine B and 0.4% penicillin–strep-
tomycin). Cultures were started in a regular, 25% horse
serum-containing medium which was gradually replaced
(from DIV 4th until 7th) by a serum-free, deﬁned-solution-
based medium. This medium contained DMEM/F12 50%
and additionally N2A (1:10; Gibco) and B27 supplement
(1:100; Gibco) without serum (the rest of compounds
remained the same). Cultures were maintained in a moist
atmosphere of air and 5% CO2,a t3 6 C for 14–16 days.
Induction of Glutamatergic Stress
After 10 days in culture, excitotoxic stress was induced by
adding 100 lM N-methyl-D-aspartate (NMDA, Sigma),
for 3 h. Then the slices were transferred to the fresh culture
medium. Biphalin (0.025–0.1 lM) or morphine (0.1 or
3 lM) were applied together with NMDA or with the delay
of 0.5, 1 or 1.5 h and were present throughout the experi-
ment (up to 24 h). To block opioid receptors 10 nM nal-
trexone (Sigma) was added together with NMDA and
biphalin or morphine and was present throughout the
experiment according to the paradigm shown in Fig. 1.
Analysis of Cell Death
Cell death was quantiﬁed in the manner described previ-
ously [21]. The ﬂuorescent cell-death marker propidium
iodide (PI) was present in the medium from 24 h prior to
the experiments and throughout the recovery period. The
relative extent of cell death was calculated from each
standardized CA1 region as follows: % of dead cells =
(experimental ﬂuorescent intensity [FI] - background FI)/
(maximal FI - background FI) 9 100, where maximal FI
was obtained by killing all cells with exposure to 1 mM
NMDA.
Results
Neuroprotection Exerted by Biphalin After
Glutamatergic Stress In Vitro
We have found that biphalin, in all tested concentrations,
revealed signiﬁcant cell protection in vitro, in stable tem-
perature conditions (36C), reducing the number of PI
labeled cells after injury by more than half. A gradual
increase in cell death was observed from 0 to 24 h after the
insult (Fig. 2a). At 24 h after NMDA stress 61.9 ± 0.18%
(n = 24)ofCA1layerneuronswerePIpositive.Application
of 0.025, 0.05 or 0.1 lM biphalin decreased the amount of
dead cells to 21.3 ± 0.17% (n = 16), 29.3 ± 0.3% (n =
16), and 22.5 ± 0.24% (n = 24), respectively in NMDA
challenged slices (Fig. 2b). Biphalin alone did not change
the viabilityofthe slices.Insuchasameexperimental setup,
similar protection was given by 3 lM morphine decreasing
the number of PI positive cells in CA1 region up
30.9 ± 0.19%(n = 8),aswellasapplicationofmorphinein
0.1 lMconcentrationwasresultedin29.9 ± 0.46%(n = 8)
PI positive cells after NMDA injury (Fig. 2b).
Involvement of Opioid Receptors in Neuroprotection
Exerted by Biphalin In Vitro
To explore the involvement of opioid receptors in biphalin-
evoked protection in OHC, together with 0.1 lM biphalin
and excitotoxic stress naltrexone, known multi-opioid
receptor blocker was added. The optimal concentrations of
naltrexone was set based on the data from studies testing the
0.5, 1, 10, 50 nM naltrexone on PI staining of neurons in
Fig. 1 Experimental protocol used to study the effect of single dose
of biphalin (BIPH) or morphine (MPH) on neurons survival in vitro in
the model of organotypic hippocampal cultures (OHC) after 100 lM
NMDA injury. DIV days in vitro, PI propidium iodide, HS horse
serum, Ntx naltrexone
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123control, unchallenged OHC (data not shown). To further
experiments 10 nM naltrexone was applied; it was the
highest tested concentration that did not impair the neurons
in the control slices. Here we show that after NMDA injury
and naltrexone application, the neuroprotective potential of
0.1 lM biphalin was abolished and resulted in 44.2 ±
0.39% (n = 8) of PI stained cells versus 22.5 ± 0.24%
(n = 24) being observed in naltrexone free samples
(Fig. 2b).While10 nMnaltrexonewasappliedwithNMDA
the number of PI positive cells was 48.7 ± 0.28% (n = 8)
and did not signiﬁcantly differ from NMDA alone chal-
lenged OHC.
Therapeutic Window of Biphalin Neuroprotection
In Vitro
Next we have shown that biphalin was a potent neuro-
protectant even it was applied 1.5 h after NMDA
application (Fig. 3). Application of 0.1 lM biphalin 0.5, 1
or 1.5 h after NMDA challenge decreased the amount of
dead cells to 23.1 ± 0.43% (n = 16), 33 ± 0.3%
(n = 16), and 29.7 ± 0.3% (n = 24), what resulted in 63,
47 and 52% of protection, respectively.
Discussion
In the reported experiments, the organotypic hippocampal
cultures challenged with NMDA to assess the neuropro-
tective potential of biphalin and to compare it to the known
protection effects of opioid analgesic ‘‘gold standard’’,
morphine [18, 19] have been used. In primary experiments,
as was reported previously [22], relatively high dose of
morphine (3 lM) has been used. In our studies the
administrated dose induced survival of about 50% of hip-
pocampal cells. Furthermore, we were observed a similar
protective effect at a dose of morphine reduced even
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Fig. 2 Neuroprotective effect evoked by biphalin (BIPH) in vitro in
organotypic hippocampal cultures (OHC). a Inverted ﬂuorescent
images of propidium iodide-stained hippocampal slices 24 h after
transient glutamatergic (100 lM NMDA, 3 h) stress. Damage was
detected mostly in the CA1 area (deﬁned by dotted lines). BIPH in the
different concentrations (0.025–0.1 lM), morphine (MPH) (0.1,
3 lM) or naltrexone (Ntx) (10 nM) were added to the medium
together with NMDA and were present till the end of the experiment.
b Quantitative analysis of cell death of OHC, 24 h after glutamatergic
stress and single dose of BIPH, MPH, naltrexone (Ntx) or combina-
tion of the drugs. The results are expressed as the mean ± SD
(n = 9–24) of propidium iodide (PI) positive cells from at least three
independent experiments. Values are considered signiﬁcant where
*P\0.05 or **P\0.01 versus NMDA treated cultures or
#P\0.01 versus control
0
10
20
30
40
50
60
70
80
c
o
n
t
r
o
l
N
M
D
A
N
M
D
A
+
B
I
P
H
/
0
h
N
M
D
A
+
B
I
P
H
/
0
.
5
h
N
M
D
A
+
B
I
P
H
/
1
.
0
h
N
M
D
A
+
B
I
P
H
/
1
.
5
h
P
I
 
u
p
t
a
k
e
 
i
n
 
C
A
 
r
e
g
i
o
n
%
 
o
f
 
d
a
m
a
g
e
*
#
*
**
**
Fig. 3 Neuroprotection evoked by delayed application of the single
dose of biphalin (BIPH) in vitro in organotypic hippocampal culture
(OHC) challenged with NMDA (100 lM) for 3 h. Quantitative
analysis of cell death of OHC, 24 h after glutamatergic stress and
0.1 lM BIPH application at 0.5, 1 or 1.5 h after NMDA. The results
are expressed as the mean ± SD (n = 16–24) of propidium iodide
(PI) positive cells. Values are considered signiﬁcant where *P\0.05
or **P\0.01 versus NMDA treated cultures or #P\0.05 versus
control
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12330 times. The obtained ceiling protective effect may be
directly related to proportion of cells containing MOP
receptor types on cell membranes.
The application of biphalin, multitarget opioid ligand
caused also a protective effect even at the lowest dose as
0.025 lM. Similar to morphine the application of three
different doses of biphalin resulted in ceiling effect.
Although this effect has been observed in protection of
larger proportion, almost 65% of hippocampal cells. This
results may indicates of the synergic neuroprotective
interaction(s) of all types of opioid receptors.
The strong neuroprotective effect of biphalin was
abolished by naltrexone, opioid multireceptor antagonist.
This suggests exclusive involvement of opioid receptors in
the mechanisms of biphalin neuroprotection. The small
dose dependent effect of both ligands possibly depends on
the unequal expression of opioid receptors in neurons
populations.
Although, most of available studies indicate that all
opioid receptors are involved in neuroprotection, some
authors report contradictory results. Ammon-Treiber et al.
[23] demonstrated that morphine exposure increases the
neurotoxic effect of hippocampal hypoxia/hypoglycemia in
a concentration dependent manner. They showed that 1 h
morphine perfusion, immediately followed by a short
hypoxic/hypoglycemic episode, resulted in an impaired
restoration of evoked ﬁeld potentials in the CA1 region as
compared to untreated control brain slices undergoing
hypoxia/hypoglycemia without drug pretreatment. In con-
trary, Zhao et al. [8] reported that exposure to morphine
immediately or at 24 h before oxygen–glucose deprivation,
reduced the oxygen–glucose deprivation-induced neuronal
death in the CA1 region of the rat hippocampal slice cul-
tures [8]. Morphine has preferential afﬁnity to MOR
receptors however, the studies have suggested that its
protection from myocardial or neuronal injury occurs by
activation of DOP-opioid receptor [24, 25]. DOPs may be
topically involved in neuroprotection through a Gi-depen-
dent manner. Extensive studies with DOR selective ligands
in vivo and in vitro conﬁrm neuroprotective effects of DOP
activation [26]. DOP activation attenuates oxidative injury
in the brain exposed to ischemia/reperfusion by enhancing
antioxidant ability and inhibiting caspase activity [27].
It has been suggested that KOP activation is also involved
in morphine protection mechanisms as well [28, 29].
Reported neurodegenerative properties of dynorphins,
endogenous KOR ligands are caused by their metabolites,
des-Tyr-dynorphins [30].
Our results excellently harmonize with just published
results of Yang et al. [31]. They described biphalin ability
for reducing brain edema formation using both in vitro and
in vivo models of stroke. For the in vitro model of ische-
mia, hippocampal slices were exposed to oxygen glucose
deprivation (OGD) conditions, what resulted in increased
hippocampal water content. Interestingly, biphalin exhib-
ited a greater effect in decreasing water content in OGD-
exposed hippocampal slices, compared with MOR, DOR,
and KOR selective opioid agonists. Furthermore, biphalin
decreased edema and infarct ratios, and neuronal recovery
from stroke in a permanent middle cerebral artery occlu-
sion (MCAO) model of focal ischemia.
In conclusion, our data conﬁrm that opioid ligands, in
addition to their primary antinociceptive activity, may play
neuroprotective role in neuropathological conditions
resulted from brain ischemia. Biphalin expressed similar
neuroprotective effect to that caused by morphine. How-
ever biphalin can be administrated in much smaller doses,
which probably is possible due to the simultaneous inter-
action with DOP, MOP, KOP, three types of opioid
receptors.
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